{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:51:32Z","timestamp":1785210692314,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":1462,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54NS065768"],"award-info":[{"award-number":["U54NS065768"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016650","name":"Rare Diseases Clinical Research Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016650","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.kint.2022.03.023","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T21:45:48Z","timestamp":1650923148000},"page":"173-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["A novel unbiased method reveals progressive podocyte globotriaosylceramide accumulation and loss with age in females with Fabry disease"],"prefix":"10.1016","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0904-6721","authenticated-orcid":false,"given":"Behzad","family":"Najafian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelio","family":"Silvestroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Sokolovskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"T\u00f8ndel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Svarstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Obrisca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gener","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrl D.","family":"Holida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2022.03.023_bib1","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","article-title":"Fabry\u2019s disease","volume":"372","author":"Zarate","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2022.03.023_bib2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.kint.2022.03.023_bib3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/08035320600618809","article-title":"Disease manifestations and X inactivation in heterozygous females with Fabry disease","volume":"95","author":"Maier","year":"2006","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.kint.2022.03.023_bib4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.kint.2022.03.023_bib5","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s10897-008-9179-7","article-title":"Disease rarity, carrier status, and gender: a triple disadvantage for women with Fabry disease","volume":"17","author":"Gibas","year":"2008","journal-title":"J\u00a0Genet Couns"},{"key":"10.1016\/j.kint.2022.03.023_bib6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang","year":"2007","journal-title":"Genet Med"},{"key":"10.1016\/j.kint.2022.03.023_bib7","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.kint.2022.03.023_bib8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1146\/annurev-med-050311-163340","article-title":"Podocyte biology and pathogenesis of kidney disease","volume":"64","author":"Reiser","year":"2013","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.kint.2022.03.023_bib9","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1523-1755.2005.67097.x","article-title":"Pathways to nephron loss starting from glomerular diseases-insights from animal models","volume":"67","author":"Kriz","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.03.023_bib10","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.03.023_bib11","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.03.023_bib12","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1681\/ASN.2010090963","article-title":"Podocyte injury damages other podocytes","volume":"22","author":"Matsusaka","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.03.023_bib13","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1681\/ASN.2014080752","article-title":"Glomerular aging and focal global glomerulosclerosis: a podometric perspective","volume":"26","author":"Hodgin","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.03.023_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112188","article-title":"Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease","volume":"9","author":"Mauer","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2022.03.023_bib15","doi-asserted-by":"crossref","first-page":"F333","DOI":"10.1152\/ajprenal.00478.2012","article-title":"The podocyte's response to stress: the enigma of foot process effacement","volume":"304","author":"Kriz","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2022.03.023_bib16","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1136\/jmedgenet-2017-104826","article-title":"Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment","volume":"54","author":"Mauer","year":"2017","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.kint.2022.03.023_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152812","article-title":"One year of enzyme replacement therapy reduces globotriaosylceramide inclusions in podocytes in male adult patients with Fabry disease","volume":"11","author":"Najafian","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2022.03.023_bib18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/jmg.14.2.91","article-title":"Heterozygote detection in angiokeratoma corporis diffusum (Anderson-Fabry disease): studies on plasma, leucocytes, and hair follicles","volume":"14","author":"Spence","year":"1977","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.kint.2022.03.023_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.ajkd.2005.10.014","article-title":"Timed urine collections are not needed to measure urine protein excretion in clinical practice","volume":"47","author":"Gaspari","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2022.03.023_bib20","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/humu.22981","article-title":"HGVS recommendations for the description of sequence variants: 2016 update","volume":"37","author":"den Dunnen","year":"2016","journal-title":"Hum Mutat"},{"key":"10.1016\/j.kint.2022.03.023_bib21","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1053\/j.ajkd.2013.12.006","article-title":"GFR estimation: from physiology to public health","volume":"63","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2022.03.023_bib22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.03.023_bib23","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease","volume":"79","author":"Najafian","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.03.023_bib24","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1681\/ASN.2019050497","article-title":"Accumulation of globotriaosylceramide in podocytes in Fabry nephropathy is associated with progressive podocyte loss","volume":"31","author":"Najafian","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.03.023_bib25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ki.1978.32","article-title":"Early renal changes in hemizygous and heterozygous patients with Fabry's disease","volume":"13","author":"Gubler","year":"1978","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.03.023_bib26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00428-008-0653-2","article-title":"Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy","volume":"453","author":"Valbuena","year":"2008","journal-title":"Virchows Arch"},{"key":"10.1016\/j.kint.2022.03.023_bib27","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/diabetes.54.6.1626","article-title":"From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy","volume":"54","author":"Wolf","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2022.03.023_bib28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13023-021-01803-7","article-title":"Hypertrophy of unaffected cardiomyocytes correlates with severity of cardiomyopathy in female patients with Fabry disease","volume":"16","author":"Chimenti","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.kint.2022.03.023_bib29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ymgme.2014.11.005","article-title":"Absence of alpha-galactosidase cross-correction in Fabry heterozygote cultured skin fibroblasts","volume":"114","author":"Fuller","year":"2015","journal-title":"Mol Genet Metab"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253822003416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253822003416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:11:54Z","timestamp":1782958314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253822003416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0085253822003416"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2022.03.023","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel unbiased method reveals progressive podocyte globotriaosylceramide accumulation and loss with age in females with Fabry disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2022.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}